Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
46
AYTU Quote, Financials, Valuation and Earnings
Last price:
$2.57
Seasonality move
:
-20.81%
Day range:
$2.44 - $2.60
52-week range:
$0.95 - $2.82
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.43x
P/B ratio:
1.12x
Volume:
134.5K
Avg. volume:
76K
1-year change:
84.78%
Market cap:
$26M
Revenue:
$66.4M
EPS (TTM):
-$3.05
Analysts' Opinion
-
Consensus RatingAytu Biopharma, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $9.33, Aytu Biopharma, Inc. has an estimated upside of 266.01% from its current price of $2.55.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $7.00 representing 100% downside risk from its current price of $2.55.
Fair Value
-
According to the consensus of 2 analysts, Aytu Biopharma, Inc. has 266.01% upside to fair value with a price target of $9.33 per share.
AYTU vs. S&P 500
-
Over the past 5 trading days, Aytu Biopharma, Inc. has overperformed the S&P 500 by 10.76% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Aytu Biopharma, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Aytu Biopharma, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Aytu Biopharma, Inc. reported revenues of $13.9M.
Earnings Growth
-
Aytu Biopharma, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Aytu Biopharma, Inc. reported earnings per share of -$0.08.
Enterprise value:
21.8M
EV / Invested capital:
0.42x
Price / LTM sales:
0.43x
EV / EBIT:
18.45x
EV / Revenue:
0.34x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-4.88x
Price / Operating cash flow:
28.82x
Enterprise value / EBITDA:
3.67x
Gross Profit (TTM):
$39.8M
Return On Assets:
-10.99%
Net Income Margin (TTM):
-20.9%
Return On Equity:
-48.36%
Return On Invested Capital:
-26.96%
Operating Margin:
-10.83%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $97.6M | $63.9M | $63.7M | $16.6M | $13.9M | |
| Gross Profit | $57.1M | $44.3M | $39.8M | $11.1M | $8.7M | |
| Operating Income | -$11.5M | $1.3M | $1.2M | -$146K | -$1.5M | |
| EBITDA | -$3M | $7.6M | $5.9M | $1.3M | -$701K | |
| Diluted EPS | -$47.04 | -$1.22 | -$3.05 | $0.16 | -$0.08 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $89M | $74.4M | $70.6M | $60.7M | $81.1M | |
| Total Assets | $227.7M | $150M | $132.9M | $115.8M | $125M | |
| Current Liabilities | $98M | $73.2M | $65.5M | $61.3M | $66M | |
| Total Liabilities | $116.2M | $101.7M | $100.7M | $86M | $101.8M | |
| Total Equity | $111.5M | $48.3M | $32.2M | $29.8M | $23.2M | |
| Total Debt | $28.1M | $30.7M | $30.7M | $13.4M | $13.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $3.7M | -$2.4M | -$1.4M | -$1.2M | -$618K | |
| Cash From Investing | -$235K | $128K | -$2.9M | $381K | -- | |
| Cash From Financing | -$7.3M | $2.4M | $16.8M | $911K | $2.3M | |
| Free Cash Flow | $3.7M | -$2.8M | -$4.5M | -$1.3M | -$618K | |
AYTU
Sector
Market Cap
$26M
$27.9M
Price % of 52-Week High
90.43%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
-92.5%
-1.49%
1-Year Price Total Return
84.78%
-16.66%
Beta (5-Year)
0.281
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$2.40
200-day SMA
Buy
Level
$1.95
Bollinger Bands (100)
Buy
Level
2.06 - 2.4
Chaikin Money Flow
Buy
Level
41.7M
20-day SMA
Buy
Level
$2.24
Relative Strength Index (RSI14)
Buy
Level
68.45
ADX Line
Buy
Level
27.92
Williams %R
Sell
Level
-19.3548
50-day SMA
Buy
Level
$2.21
MACD (12, 26)
Buy
Level
0.10
25-day Aroon Oscillator
Buy
Level
72
On Balance Volume
Neutral
Level
77.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.8852)
Sell
CA Score
(Annual)
Level (-1.5718)
Buy
Beneish M-Score
(Annual)
Level (-2.6399)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (3.8365)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Denver, CO.
Stock Forecast FAQ
In the current month, AYTU has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AYTU average analyst price target in the past 3 months is $9.33.
-
Where Will Aytu Biopharma, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Aytu Biopharma, Inc. share price will rise to $9.33 per share over the next 12 months.
-
What Do Analysts Say About Aytu Biopharma, Inc.?
Analysts are divided on their view about Aytu Biopharma, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Aytu Biopharma, Inc. is a Sell and believe this share price will drop from its current level to $7.00.
-
What Is Aytu Biopharma, Inc.'s Price Target?
The price target for Aytu Biopharma, Inc. over the next 1-year time period is forecast to be $9.33 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is AYTU A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Aytu Biopharma, Inc. is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AYTU?
You can purchase shares of Aytu Biopharma, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Aytu Biopharma, Inc. shares.
-
What Is The Aytu Biopharma, Inc. Share Price Today?
Aytu Biopharma, Inc. was last trading at $2.57 per share. This represents the most recent stock quote for Aytu Biopharma, Inc.. Yesterday, Aytu Biopharma, Inc. closed at $2.55 per share.
-
How To Buy Aytu Biopharma, Inc. Stock Online?
In order to purchase Aytu Biopharma, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get AYTU Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
AYTU
Sector
P/E ratio
--
23.85x
PEG ratio
-0.01x
-0.01x
P/B ratio
1.12x
1.81x
Price / LTM sales
0.43x
1.58x
Growth Metrics
AYTU
Sector
Revenue growth
-16.21%
4.62%
Earnings growth
-147.72%
10.5%
Revenue (5-year growth)
19.16%
6.5%
Earnings forecast
-$0.20
-$0.21
Profitability
AYTU
Sector
Profitability FY 2025
$42.1M
$3.6M
Return on invested capital
-26.96%
-31.87%
Return on assets
-10.99%
-28.18%
Return on equity
-48.36%
-37.63%
Earnings Date
Last Earnings Date
Dec
21
Next Earnings Date
Dec
21
Estimated Next Earnings Date
Mar
22
Balance Sheet
AYTU
Sector
Total cash
$32.6M
$26.4M
Short term investments
--
$25.7M
Total assets
$124.4M
$76.9M
Long term debt
$13.3M
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
